Clinical trial NCT01295580: Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis Pain
Official title: A Multicenter, Randomized, Double-blind, Parallel, Active-controlled Clinical Trial With Non-inferiority Comparison to Evaluate Efficacy and Safety of Intra-articular Injection of DUROLANE® vs. ARTZ® in Treatment of Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Knee Osteoarthritis
Lead sponsor: Bioventus LLC
Sponsor class: INDUSTRY
Collaborators: name: Smith & Nephew, Inc.
First posted: 2011-02-14
Enrollment: 349
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the comparative safety and efficacy of intra-articular injection of hyaluronic acid, obtained from two different sources, in the treatment of osteoarthritic pain of the knee.

Detailed description: This is a multicenter, randomized, double blind, parallel-controlled clinical trial using a non-inferiority comparison to evaluate the efficacy and safety of an intra-articular injection of Durolane® vs Artz® in the treatment of knee osteoarthritis. Subjects will be randomized 1:1 to receive either Durolane or Artz. All subjects will be followed up for 26 weeks from the initial treatment.The screening period is expected to be up to 2 weeks in duration before the baseline visit. Each subject will provide a written informed consent and undergo a qualifying screening. Assessment at screening will include postero-anterior view of standing weight-bearing semi-flexed radiographs of the study knee. The osteoarthritis changes of the study knee will be graded 0,1,2,3 or 4 according to the Kellgren-Lawrence radiographic scoring criteria. Radiographic assessment will be made by an assigned and well trained investigator at each study center. The study knee and contralateral knee will use the Likert WOMAC 5-point scoring for pain assessment.

Physical examination of the knees and vital signs will be performed (this examination will be repeated at end).

Eligibility criteria: Inclusion Criteria:

* Subject (female or male) 40-80 years of age, inclusive
* Documented diagnosis of mild to moderate osteoarthritis of the study knee that fulfil the ACR(American College of Rheumatology) criteria
* Radiographic evidence of osteoarthritis in the study knee (Kellgren Lawrence radiographic score is 2 or 3)

Exclusion Criteria:

* Clinically apparent tense effusion of the study knee on examination determined by either a positive bulge sign or positive ballottement of the patella
* Kellgren-Lawrence radiographic score 0, 1 or 4 in the study knee
* Symptomatic osteoarthritis of the contralateral knee or of either hip that is not responsive to acetaminophen/paracetamol and/or requires any protocol prohibited therapies

Primary outcomes:
measure: WOMAC (Western Ontario and McMaster Osteoarthritis Index) Pain Subscale Change From Baseline
timeFrame: over 18 weeks (week timepoints 6, 10, 14, and 18)
Secondary outcomes:
measure: WOMAC (Western Ontario and McMaster Osteoarthritis Index) Pain Subscale Change From Baseline
timeFrame: over 26 weeks (week 6, 10, 14, 18, and 26)
measure: WOMAC (Western Ontario and McMaster Osteoarthritis Index) Physical Function Subscale Change From Baseline
timeFrame: over 18 weeks (week timepoints 6, 10, 14, and 18)
measure: WOMAC (Western Ontario and McMaster Osteoarthritis Index) Physical Function Subscale Change From Baseline
timeFrame: over 26 weeks (week timepoints 6, 10, 14, 18, and 26)
measure: Subject Global Assessment Change From Baseline
timeFrame: over 18 weeks (week timepoints 6, 10, 14, and 18)
measure: Subject Global Assessment Change From Baseline
timeFrame: over 26 weeks (week timepoints 6, 10, 14, 18, and 26)
measure: WOMAC (Western Ontario and McMaster Osteoarthritis Index) Knee Stiffness Subscale Change From Baseline
timeFrame: over 18 weeks (week timepoints 6, 10, 14, and 18)
measure: WOMAC (Western Ontario and McMaster Osteoarthritis Index) Knee Stiffness Subscale Change From Baseline
timeFrame: over 26 weeks (week timepoints 6, 10, 14, 18, and 26)
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Frienship Hospital
city: Beijing
country: China
facility: Beijing General Military Hospital
city: Beijing
country: China
facility: Beijing University #3 Hospital
city: Beijing
country: China
facility: Beijing University People's Hospital
city: Hangzhou
country: China
facility: Zhejiang #2 Hospital
city: Shanghai
country: China
facility: Shanghai #6 People's Hospital
city: Shanghai
country: China
facility: Shanghai #9 People's Hospital
Study officials:
affiliation: People Hospital of Beijing University No. 11 South Ave., Xizhimen, Beijing
name: Jianhao Lin, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Zhang H, Zhang K, Zhang X, Zhu Z, Yan S, Sun T, Guo A, Jones J, Steen RG, Shan B, Zhang J, Lin J. Comparison of two hyaluronic acid formulations for safety and efficacy (CHASE) study in knee osteoarthritis: a multicenter, randomized, double-blind, 26-week non-inferiority trial comparing Durolane to Artz. Arthritis Res Ther. 2015 Mar 10;17(1):51. doi: 10.1186/s13075-015-0557-x.